A detailed history of Susquehanna International Group, LLP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 20,299 shares of NUVB stock, worth $44,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,299
Holding current value
$44,860
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$2.58 - $3.69 $52,371 - $74,903
20,299 New
20,299 $59,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $134,266 - $213,987
139,861 Added 983.41%
154,083 $232,000
Q3 2023

Nov 14, 2023

SELL
$1.26 - $2.1 $40,170 - $66,950
-31,881 Reduced 69.15%
14,222 $19,000
Q2 2023

Aug 11, 2023

SELL
$1.56 - $1.84 $113,031 - $133,319
-72,456 Reduced 61.11%
46,103 $82,000
Q1 2023

May 16, 2023

BUY
$1.6 - $2.48 $149,097 - $231,101
93,186 Added 367.26%
118,559 $196,000
Q4 2022

Feb 14, 2023

SELL
$1.68 - $2.5 $84,500 - $125,745
-50,298 Reduced 66.47%
25,373 $48,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $21,944 - $305,710
75,671 New
75,671 $170,000
Q2 2022

Aug 15, 2022

SELL
$3.24 - $5.85 $38,319 - $69,187
-11,827 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $222,446 - $427,001
-48,358 Reduced 80.35%
11,827 $62,000
Q4 2021

Feb 14, 2022

BUY
$7.75 - $10.05 $291,136 - $377,538
37,566 Added 166.08%
60,185 $512,000
Q3 2021

Nov 15, 2021

SELL
$7.78 - $10.0 $387,490 - $498,060
-49,806 Reduced 68.77%
22,619 $225,000
Q2 2021

Aug 11, 2021

BUY
$9.22 - $14.48 $362,226 - $568,875
39,287 Added 118.56%
72,425 $674,000
Q1 2021

May 17, 2021

BUY
$9.0 - $14.57 $298,242 - $482,820
33,138 New
33,138 $346,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $480M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.